NeoStem is engaged in the development of proprietary cell therapy products, and operating a contract development and manufacturing organization providing services in the regenerative medicine industry. Co. is developing therapies to address ischemia through its CD34 Cell Program. AMR-001 is Co.'s product candidate in this program and is being developed to treat damaged heart muscle following an acute myocardial infarction (heart attack). Another platform technology Co. is developing uses T Regulatory Cells to treat diseases caused by imbalances in the immune system. In addition, pre-clinical assets include Co.'s VSEL™ (Very Small Embryonic Like) Technology regenerative medicine platform.
|
Free NBS Email Alerts: Get SEC Filing Alerts Get Dividend Alerts |
Strong Buy (4.00 out of 4) 89th percentile
(ranked higher than approx. 89% of all stocks covered)
Based on Zacks ABR data; powered by Xignite |